At ASH 2025, iMMagine-1 data showed that anito-cel has a favorable and durable safety profile with low rates of severe CRS, neurotoxicity, and infections.

Patients share their unexpected journeys with multiple myeloma, revealing challenges and resilience in the face of a cancer ...

Drs Joseph Mikhael and Shaji Kumar discuss the future of multiple myeloma, including enhanced diagnostics for detecting ...

For Rosemarie Fileen, something was amiss. "This was around 2017, and I was not feeling 100% myself," recalls the now 51-year ...

An in vivo chimeric antigen receptor T-cell therapy administered without lymphodepletion exhibited activity among patients with advanced multiple myeloma, according to findings presented at ASH Annual ...

Although the readout was only from four multiple myeloma patients, attendees at the meeting wondered at how far the CAR T-cell therapy field has come.

ORLANDO -- A gene therapy that could transform CAR T-cell treatment achieved rapid and potentially durable measurable ...

Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted ...

A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...

Regeneron's new antibody drug, Lynozyfic, shows promise in eradicating residual multiple myeloma without the need for bone marrow transplants, according to a small mid-stage trial. The treatment ...

Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific ...

In addition to being a highly efficacious treatment for R/R multiple myeloma as early as the first relapse, researchers noted that the Tec-Dara combination could be more accessible than other ...